MARKET

EDIT

EDIT

Editas Medicine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

30.64
-1.38
-4.31%
After Hours: 30.85 +0.21 +0.69% 18:20 01/17 EST
OPEN
32.20
PREV CLOSE
32.02
HIGH
32.20
LOW
30.42
VOLUME
1.01M
TURNOVER
--
52 WEEK HIGH
34.37
52 WEEK LOW
19.00
MARKET CAP
1.56B
P/E (TTM)
-12.4028
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EDIT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

EDIT News

  • European ruling threatens Broad's CRISPR gene-editing patents
  • American City Business Journals.12h ago
  • The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
  • Benzinga.1d ago
  • The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance
  • Benzinga.2d ago
  • Editas teams up with Sandhill Therapeutics in cancer; shares up 2% premarket
  • Seeking Alpha - Article.4d ago

More

Industry

Biotechnology & Medical Research
-0.10%
Pharmaceuticals & Medical Research
+0.07%

Hot Stocks

Name
Price
%Change

About EDIT

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).
More

Webull offers Editas Medicine Inc (EDIT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.